Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

Evaluating the safety of a rotavirus vaccine: the REST of the story.

Heyse JF, Kuter BJ, Dallas MJ, Heaton P; REST Study Team..

Clin Trials. 2008;5(2):131-9. doi: 10.1177/1740774508090507.

2.

Safety of the pentavalent rotavirus vaccine (PRV), RotaTeq(®), in Kenya, including among HIV-infected and HIV-exposed infants.

Laserson KF, Nyakundi D, Feikin DR, Nyambane G, Cook E, Oyieko J, Ojwando J, Rivers SB, Ciarlet M, Neuzil KM, Breiman RF.

Vaccine. 2012 Apr 27;30 Suppl 1:A61-70. doi: 10.1016/j.vaccine.2011.09.026.

PMID:
22520138
3.

Real-time surveillance to assess risk of intussusception and other adverse events after pentavalent, bovine-derived rotavirus vaccine.

Belongia EA, Irving SA, Shui IM, Kulldorff M, Lewis E, Yin R, Lieu TA, Weintraub E, Yih WK, Li R, Baggs J; Vaccine Safety Datalink Investigation Group..

Pediatr Infect Dis J. 2010 Jan;29(1):1-5. doi: 10.1097/INF.0b013e3181af8605.

PMID:
19907356
4.

Rotavirus live, oral, pentavalent vaccine.

Tom-Revzon C.

Clin Ther. 2007 Dec;29(12):2724-37. doi: 10.1016/j.clinthera.2007.12.018. Review.

PMID:
18201590
5.

Postlicensure monitoring of intussusception after RotaTeq vaccination in the United States, February 1, 2006, to September 25, 2007.

Haber P, Patel M, Izurieta HS, Baggs J, Gargiullo P, Weintraub E, Cortese M, Braun MM, Belongia EA, Miller E, Ball R, Iskander J, Parashar UD.

Pediatrics. 2008 Jun;121(6):1206-12. doi: 10.1542/peds.2007-3793.

PMID:
18519491
6.

Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine.

Vesikari T, Matson DO, Dennehy P, Van Damme P, Santosham M, Rodriguez Z, Dallas MJ, Heyse JF, Goveia MG, Black SB, Shinefield HR, Christie CD, Ylitalo S, Itzler RF, Coia ML, Onorato MT, Adeyi BA, Marshall GS, Gothefors L, Campens D, Karvonen A, Watt JP, O'Brien KL, DiNubile MJ, Clark HF, Boslego JW, Offit PA, Heaton PM; Rotavirus Efficacy and Safety Trial (REST) Study Team..

N Engl J Med. 2006 Jan 5;354(1):23-33.

7.

Safety and efficacy of the pentavalent human-bovine (WC3) reassortant rotavirus vaccine in healthy premature infants.

Goveia MG, Rodriguez ZM, Dallas MJ, Itzler RF, Boslego JW, Heaton PM, DiNubile MJ; REST Study Team..

Pediatr Infect Dis J. 2007 Dec;26(12):1099-104.

PMID:
18043445
8.

Intussusception and rotavirus vaccination: a review of the available evidence.

Patel MM, Haber P, Baggs J, Zuber P, Bines JE, Parashar UD.

Expert Rev Vaccines. 2009 Nov;8(11):1555-64. doi: 10.1586/erv.09.106. Review.

PMID:
19863248
9.

Postmarketing monitoring of intussusception after RotaTeq vaccination--United States, February 1, 2006-February 15, 2007.

Centers for Disease Control and Prevention (CDC)..

MMWR Morb Mortal Wkly Rep. 2007 Mar 16;56(10):218-22.

10.

RotaTeq, a pentavalent rotavirus vaccine: efficacy and safety among infants in Europe.

Vesikari T, Itzler R, Karvonen A, Korhonen T, Van Damme P, Behre U, Bona G, Gothefors L, Heaton PM, Dallas M, Goveia MG.

Vaccine. 2009 Dec 11;28(2):345-51. doi: 10.1016/j.vaccine.2009.10.041.

PMID:
19879226
11.

Rotavirus vaccine (RotaTeq).

Keating GM.

Paediatr Drugs. 2006;8(3):197-202; discussion 203-4. Review.

PMID:
16774301
12.

Clinical trials of rotavirus vaccines in Europe.

Vesikari T, Giaquinto C, Huppertz HI.

Pediatr Infect Dis J. 2006 Jan;25(1 Suppl):S42-7. Review.

PMID:
16397428
13.

Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis.

Ruiz-Palacios GM, Pérez-Schael I, Velázquez FR, Abate H, Breuer T, Clemens SC, Cheuvart B, Espinoza F, Gillard P, Innis BL, Cervantes Y, Linhares AC, López P, Macías-Parra M, Ortega-Barría E, Richardson V, Rivera-Medina DM, Rivera L, Salinas B, Pavía-Ruz N, Salmerón J, Rüttimann R, Tinoco JC, Rubio P, Nuñez E, Guerrero ML, Yarzábal JP, Damaso S, Tornieporth N, Sáez-Llorens X, Vergara RF, Vesikari T, Bouckenooghe A, Clemens R, De Vos B, O'Ryan M; Human Rotavirus Vaccine Study Group..

N Engl J Med. 2006 Jan 5;354(1):11-22.

15.

Intussusception risk and disease prevention associated with rotavirus vaccines in Australia's National Immunization Program.

Carlin JB, Macartney KK, Lee KJ, Quinn HE, Buttery J, Lopert R, Bines J, McIntyre PB.

Clin Infect Dis. 2013 Nov;57(10):1427-34. doi: 10.1093/cid/cit520.

16.

An analysis of rotavirus vaccine reports to the vaccine adverse event reporting system: more than intussusception alone?

Haber P, Chen RT, Zanardi LR, Mootrey GT, English R, Braun MM; VAERS Working Group..

Pediatrics. 2004 Apr;113(4):e353-9.

PMID:
15060267
17.

The new pentavalent rotavirus vaccine composed of bovine (strain WC3) -human rotavirus reassortants.

Clark HF, Offit PA, Plotkin SA, Heaton PM.

Pediatr Infect Dis J. 2006 Jul;25(7):577-83. Review.

PMID:
16804425
18.

The human rotavirus vaccine RIX4414 in infants: a review of safety and tolerability.

Cheuvart B, Friedland LR, Abu-Elyazeed R, Han HH, Guerra Y, Verstraeten T.

Pediatr Infect Dis J. 2009 Mar;28(3):225-32. doi: 10.1097/INF.0b013e31819715fa. Review.

PMID:
19209095
19.

RotaTeq: Progress toward developing world access.

Goveia MG, Nelson CB, Ciarlet M.

J Infect Dis. 2010 Sep 1;202 Suppl:S87-92. doi: 10.1086/653546.

PMID:
20684723
20.

Rotavirus vaccines: targeting the developing world.

Glass RI, Bresee JS, Turcios R, Fischer TK, Parashar UD, Steele AD.

J Infect Dis. 2005 Sep 1;192 Suppl 1:S160-6.

PMID:
16088799

Supplemental Content

Support Center